Adimab and Roche have initiated a research program whereby Adimab will use its proprietary discovery platform to identify fully human antibodies against a target selected by Roche. The agreement allows Roche the right to commercialize antibodies generated from the collaboration as therapeutic and diagnostic products. Under the terms of the agreements, Adimab will receive various upfront payments, preclinical milestones and licensing fees. In addition, Adimab is eligible to receive milestones and royalties on therapeutic and diagnostic product sales.

• Roche confirmed the successful delivery of several hundred IgGs within 8 weeks of starting an antibody discovery program with Adimab. The IgGs delivered met specific criteria as outlined in the contract.

> Roche

Adimab and Merck have entered into a collaboration whereby Adimab will use its proprietary discovery platform to identify fully human antibodies against targets selected by Merck. The agreement grants Merck the right to commercialize antibodies generated from the collaboration as therapeutic products. Under the terms of the agreements, Adimab will receive various upfront payments, preclinical milestones and licensing fees. In addition, Adimab is eligible to receive milestones and royalties on therapeutic product sales.

• Merck confirmed delivery of a panel of antibodies that met criteria outlined in the original agreement within 8 weeks of the initiation of the discovery program.
• Adimab has also announced the achievement of a second milestone from its ongoing collaboration with Merck.

> Merck & Co.

Adimab and Pfizer have entered into a collaboration whereby Adimab will use its proprietary discovery platform to identify fully human antibodies against a Central Nervous System/Pain target selected by Pfizer. The agreement grants Pfizer the right to commercialize antibodies generated from the collaboration as therapeutic products. Under the terms of the agreements, Adimab will receive various upfront payments, preclinical milestones and licensing fees. In addition, Adimab is eligible to receive milestones and royalties on therapeutic and diagnostic product sales.

> Pfizer

Adimab and Novartis have entered into a collaboration whereby Adimab will use its proprietary discovery platform to identify fully human antibodies against two targets selected by Novartis. The agreement grants Novartis the right to commercialize antibodies generated from the collaboration as therapeutic and diagnostic products. Under the terms of the agreements, Adimab will receive a combination of upfront payments, license fees, clinical milestones, and royalties on therapeutic and diagnostic product sales.

> Novartis

DNA2.0 is the largest gene synthesis provider in the US, and a pioneer of several novel applications for synthetic genes including protein engineering, codon optimization and RNAi resistant genes.

As part of Adimab’s ongoing effort to efficiently integrate all aspects of therapeutic antibody discovery, the company has entered into a strategic relationship with DNA2.0. Adimab is working closely with DNA2.0 to optimize all aspects of antibody library design, antibody maturation and antibody presentation. In addition, we are systematically optimizing the expression of antibody frameworks in yeast to improve the production and formulation of therapeutic antibodies. Our relationship with DNA2.0 allows us to apply Adimab’s computational biology capabilities to the interpretation of large-scale antibody library screens and rapidly integrate them into the Adimab discovery, maturation and bio-manufacturing platform.

> DNA2.0